RET-rearranged thyroid
Showing 1 - 25 of 1,735
ALK-positive NSCLC (NSCLC), RET-positive NSCLC (NSCLC), RET-positive Thyroid Cancer Trial in Irvine, Boston (Alectinib)
Terminated
- ALK-positive Non-small Cell Lung Cancer (NSCLC)
- +2 more
-
Irvine, California
- +3 more
Aug 30, 2021
Solid Tumor, Medullary Thyroid Cancer Trial in China (Selpercatinib)
Active, not recruiting
- Solid Tumor
- Medullary Thyroid Cancer
-
Guangzhou, Guangdong, China
- +12 more
May 9, 2022
Advanced Nonhaematologic Malignancies Trial in Worldwide (BOS172738)
Active, not recruiting
- Advanced Nonhaematologic Malignancies
-
Philadelphia, Pennsylvania
- +20 more
Sep 23, 2022
RET-altered Non Small Cell Lung Cancer, Medullary Thyroid Cancer, RET-altered Papillary Thyroid Cancer Trial in Chang chun
Not yet recruiting
- RET-altered Non Small Cell Lung Cancer
- +3 more
-
Chang chun, Jilin, ChinaJinlin Province Cancer Hosipital
Dec 21, 2022
RET-altered Non Small Cell Lung Cancer, Medullary Thyroid Cancer, RET-altered Papillary Thyroid Cancer Trial in Worldwide
Active, not recruiting
- RET-altered Non Small Cell Lung Cancer
- +39 more
- pralsetinib (BLU-667)
-
Phoenix, Arizona
- +65 more
Nov 10, 2022
Malignant Thyroid Gland Tumor, Poorly Differentiated Thyroid Gland Carcinoma, Recurrent Thyroid Gland Carcinoma Trial in Houston
Recruiting
- Malignant Thyroid Gland Neoplasm
- +6 more
- Quality-of-Life Assessment
- +3 more
-
Ann Arbor, Michigan
- +1 more
Jan 24, 2023
Thyroid Cancer, Thyroid Carcinoma, Metastatic Thyroid Cancer Trial in Boston (Selpercatinib, Sodium Iodine I-131, rhTSH)
Not yet recruiting
- Thyroid Cancer
- +5 more
- Selpercatinib
- +2 more
-
Boston, MassachusettsMassachusetts General Hospital
Dec 20, 2022
NSCLC, Thyroid Tumors Trial (LOXO-260)
Temporarily not available
- Carcinoma, Non-Small-Cell Lung
- Thyroid Neoplasms
- (no location specified)
Sep 20, 2022
NSCLC, Medullary Thyroid Cancer, Solid Tumor Trial in Shanghai, Tianjin (SY-5007)
Recruiting
- Non-Small Cell Lung Cancer
- +2 more
-
Shanghai, Shanghai, China
- +1 more
Mar 17, 2022
Medullary Thyroid Cancer Trial in Worldwide (Selpercatinib, Cabozantinib, Vandetanib)
Recruiting
- Medullary Thyroid Cancer
- Selpercatinib
- +2 more
-
Birmingham, Alabama
- +148 more
Jan 18, 2023
Medullary Thyroid Cancer Trial in China (Anlotinib Hydrochloride Capsule)
Recruiting
- Medullary Thyroid Cancer
- Anlotinib Hydrochloride Capsule
-
Hefei, Anhui, China
- +18 more
Apr 14, 2023
Thyroid Carcinoma
Recruiting
- Differentiated Thyroid Carcinoma
- Medullary Thyroid Carcinoma
- Immunohistochemistry (IHC)
- +2 more
-
L'Hospitalet De Llobregat, Barcelona, Spain
- +11 more
Mar 22, 2022
Vandetanib in RET -/+ Metastatic Medullary Thyroid Cancer
Completed
- Symptomatic, Aggressive, Sporadic, Unresectable, Locally
- Advanced/Metastatic Medullary Thyroid Cancer (MTC)
- Vandetanib 300 mg
-
Belgium, Belgium
- +7 more
Oct 15, 2020
Children and Adults With Medullary Thyroid Cancer
Recruiting
- Medullary Thyroid Cancer
-
Bethesda, MarylandNational Institutes of Health Clinical Center, 9000 Rockville Pi
Apr 7, 2022
Low-risk Papillary Thyroid Cancer, Endocrine Malignancy, Thyroid Cancer Trial run by the NCI (Total Thyroidectomy (TT),
Terminated
- Low-risk Papillary Thyroid Cancer
- +2 more
- Total Thyroidectomy (TT)
- Prophylactic central neck lymph node dissection (pCND)
-
Bethesda, MarylandNational Institutes of Health Clinical Center, 9000 Rockville Pi
Sep 8, 2022
NSCLC Trial in Guangzhou (HA121-28 tablet)
Recruiting
- NSCLC
- HA121-28 tablet
-
Guangzhou, Guangdong, ChinaSun Yat-sen University Cancer Centre
Aug 2, 2022
NSCLC Trial in Worldwide (Selpercatinib, Carboplatin, Cisplatin)
Active, not recruiting
- Non-Small Cell Lung Cancer
- Selpercatinib
- +4 more
-
Berazategui, Buenos Aires, Argentina
- +195 more
Jan 30, 2023
A Taiwanese Oncogenetic Panel and Integrated Clinical Data
Recruiting
- Thyroid Cancer
- A Taiwanese Oncogenetic Panel and Integrated Clinical Data Registry Study for Advanced Thyroid Cancer Patients
-
Kaohsiung, Taiwan
- +7 more
Sep 12, 2022